Citigroup Lowers Teladoc Health Target Price to $9.00.
ByAinvest
Saturday, Jan 10, 2026 8:43 am ET1min read
TDOC--
Citigroup has maintained its 'Neutral' rating on Teladoc Health (TDOC) but lowered the target price from $10.00 to $9.00, a 10% decrease. The target price adjustment reflects Citigroup's ongoing evaluation of TDOC's potential growth. Historical ratings for TDOC have been diverse, with analysts offering varying assessments of the company's market value. The average target price for TDOC is $9.06, indicating a 21.22% upside from the current price. The average brokerage recommendation is 2.8, indicating a 'Hold' status.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet